Radiopharm Theranostics' RAD101 Hits Primary Endpoint in Brain Metastases Trial
Event summary
- RAD101 achieved 93% concordance with MRI in Phase 2b trial for brain metastases imaging.
- Late-breaking oral presentation selected for SNO26 Annual Meeting (Nov 12-15, 2026).
- FDA meeting scheduled for October 1, 2026 to align on Phase 3 trial protocol.
- Brain metastases imaging market estimated at $600M with no approved PET products.
The big picture
Radiopharm Theranostics' positive Phase 2b data positions RAD101 as a potential game-changer in brain metastases imaging, addressing a critical gap in current MRI limitations. The $600M market opportunity and lack of approved PET alternatives underscore the strategic significance of this development. Success here could redefine diagnostic standards for neuro-oncology patients.
What we're watching
- Regulatory Pathway
- Whether the FDA meeting will accelerate RAD101's Phase 3 trial initiation.
- Market Potential
- The pace at which Radiopharm can capture the $600M brain metastases imaging market.
- Clinical Validation
- How the SNO26 presentation will impact peer and investor perception of RAD101's efficacy.
Related topics